PropertyValue
?:abstract
  • • Several studies suggested Baricitinib as a potential drug for the management of COVID 19 infection through drug repurposing strategies because of its ability to act on AT2 cells and AAK1 mediated endocytosis. • Baricitinib, a Januase Kinase Inhibitor, have known to cause Lymphocytopenia, Neutropenia and Viral Reactivation. • Reported Epidemiological studies have shown that COVID 19 patients have a lesser absolute lymphocyte count closer to the threshold value. • Moreover, incidence of Co-infection for COVID 19 patients is one of the leading causes of Mortality. Baricitinib may enhance the incidence of Co-infection. • Hence, Baricitinib may not be an ideal option for Management of COVID 19.
?:creator
?:doi
  • 10.1016/j.ijantimicag.2020.105967
?:doi
?:externalLink
?:journal
  • Int_J_Antimicrob_Agents
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/04383994da0f349f314e59c9a414a9c8cc5b4448.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7128600.xml.json
?:pmcid
?:pmid
?:pmid
  • 32259575
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • PMC
?:title
  • BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
?:type
?:year
  • 2020-04-04

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/270msv5l>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/270msv5l>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all